Agilent Acquires Dowpharma Business
The purchase price was not diclosed. Agilent’s purchase assists it in its plans to add large-scale nucleic acid synthesis, purification and drying capacity to its Boulder, Colorado, facility by the end of the year.
Santa Clara, CA 5/7/08—Agilent Technologies has acquired the assets of Dowpharma’s Nucleic Acid Medicine business. The purchase is part of Agilent’s expansion of its Nucleic Acid Solutions Division, which offers therapeutic nucleic acid development services and manufacturing solutions. “Agilent will have the ability to serve customers from preclinical through large-scale commercial launch with facilities, equipment and expertise across a broad range of nucleic acid APIs,” commented James Powell, general manager of the Nucleic Acid Solutions Division.
